{
  "docId": "019de071-1981-7442-94ed-ee285d10f59b",
  "docSlug": "c18efbd116f640ca1060cd96d0c18250",
  "documentTitle": "Alkermes | Results Presentation Deck | 31 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 31,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 60,
  "notes": "Data cut off May 3, 2021.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-1981-7442-94ed-ee285d10f59b/19",
  "deckHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b",
  "deckJsonHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b.json",
  "deckAnchorHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "list",
      "text": "Cervical cancer: Of 4 evaluable patients, 2 achieved PR (1 awaiting confirmation); 3 of the 4 patients continued on therapy. Responses also observed in bladder, Hodgkin's lymphoma, breast, RCC, mucosal melanoma, head & neck, lung cancer",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9687fb7c-1ad7-4e9b-8bcf-ba37a971a946",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "For full list of prior therapies, please see ASCO 2021 poster; ** New response observed after the March 19, 2021 data cut; a Awaiting confirmation. ER+/HER2-: Estrogen Receptor+ Human Epidermal Growth Factor Receptor 2-; SCLC: Small cell lung cancer; GEJ: Esophagogastric junction; RCC: Renal cell carcinoma; SCC: Squamous cell carcinoma; PR: Partial response; uPR: Unconfirmed partial response. Data cut off May 3, 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f6dcd0e-3177-47a2-a496-cde6e67e85ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "table",
      "text": "Table showing patient-level clinical trial data for Nemvaleukin + Pembrolizumab combinations.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a5d7a04f-0d3a-4f72-af53-c94adffdca4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ARTISTRY-1: IV Nemvaleukin in Combination With Pembrolizumab PD-1/L1 Approved Tumor Cohort and Tumor-Specific Cohorts",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4bc919f9-4379-4e76-9d4e-594e8dd2b6d7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "a11967c5-16bb-4339-be72-2a3d5e66ce88",
      "evidence": "table/data: Table showing patient-level clinical trial data for Nemvaleukin + Pembrolizumab combinations.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 21,
      "from": 9,
      "beatId": "d9955255-a32f-40ae-8cd0-621b7a3219ac",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The presentation provides detailed data on ARTISTRY-1 and ARTISTRY-2 clinical trials",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 9,
      "name": "Zoom In",
      "slug": "06-zoom-in",
      "bestFor": "Technical deep-dives, case studies, detailed analysis",
      "matchId": "d7735cef-12ea-4b86-b204-a8c9a7eb598c",
      "evidence": "The presentation provides detailed data on the clinical trials",
      "position": 0,
      "objective": "What are the safety and efficacy results of Nemvaleukin Alfa in ARTISTRY-1 and ARTISTRY-2 trials?",
      "structure": "The Big Picture -> Key Area of Focus -> Specific Detail -> Implication",
      "confidence": 0.8,
      "description": "Start broad, then progressively focus on specific details that prove your point"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}